Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 2
1986 1
1987 1
1988 1
1990 2
1991 2
1993 3
2007 1
2019 1
2020 4
2021 4
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.
Hughes DA, Bichet DG, Giugliani R, Hopkin RJ, Krusinska E, Nicholls K, Olivotto I, Feldt-Rasmussen U, Sakai N, Skuban N, Sunder-Plassmann G, Torra R, Wilcox WR. Hughes DA, et al. Among authors: krusinska e. J Med Genet. 2022 Dec 21:jmedgenet-2022-108669. doi: 10.1136/jmg-2022-108669. Online ahead of print. J Med Genet. 2022. PMID: 36543533 Free article.
Corrigendum to "Long-term follow-up of renal function in patients treated with migalastat for Fabry disease" [Bichet et al., MGM Reports; 28 (2021) 100786].
Bichet DG, Torra R, Wallace E, Hughes D, Giugliani R, Skuban N, Krusinska E, Feldt-Rasmussen U, Schiffmann R, Nicholls K. Bichet DG, et al. Among authors: krusinska e. Mol Genet Metab Rep. 2021 Oct 2;29:100807. doi: 10.1016/j.ymgmr.2021.100807. eCollection 2021 Dec. Mol Genet Metab Rep. 2021. PMID: 34934630 Free PMC article.
Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPSP795 (SHP635).
Roberts MS, Gafni RI, Brillante B, Guthrie LC, Streit J, Gash D, Gelb J, Krusinska E, Brennan SC, Schepelmann M, Riccardi D, Bin Khayat ME, Ward DT, Nemeth EF, Rosskamp R, Collins MT. Roberts MS, et al. Among authors: krusinska e. J Bone Miner Res. 2019 Sep;34(9):1609-1618. doi: 10.1002/jbmr.3747. Epub 2019 Jul 26. J Bone Miner Res. 2019. PMID: 31063613 Free PMC article.
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).
Paller AS, Browning J, Nikolic M, Bodemer C, Murrell DF, Lenon W, Krusinska E, Reha A, Lagast H, Barth JA; ESSENCE Study Group. Paller AS, et al. Among authors: krusinska e. Orphanet J Rare Dis. 2020 Jun 23;15(1):158. doi: 10.1186/s13023-020-01419-3. Orphanet J Rare Dis. 2020. PMID: 32576219 Free PMC article. Clinical Trial.
24 results